Bacterial proteins: A new class of cancer therapeutics

Journal of Commercial Biotechnology

Volumn 18, Issue 1, 2012, Pages 4-10

  Chakrabarty, Ananda Mohan ^a,b,c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b CDG Therapeutics Inc   (United States)

^c Amrita Therapeutics   (India)

Author keywords

Anticancer drugs; Azurin; Bacterial proteins; Cancer eradication; Cancer prevention; Human clinical trials

Indexed keywords

ANTICANCER DRUG; AZURIN; BACTERIAL PROTEINS; CANCER ERADICATION; CANCER PREVENTION; CLINICAL TRIAL;

AMINO ACIDS; BACTERIA; CELL DEATH; CHEMOTHERAPY; DRUG PRODUCTS; ENZYME INHIBITION; EXPERIMENTS; MONOCLONAL ANTIBODIES; PEPTIDES; TOXICITY; TUMORS; VIRUSES;

DISEASES;

AZURIN; BACTERIAL PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CARCINOGEN; MONOCLONAL ANTIBODY; PROTEIN ATP 01; PROTEIN P28; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADVANCED CANCER; AIDS PATIENT; AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; CANCER CELL; CANCER GROWTH; CANCER PATIENT; CANCER PREVENTION; CANCER REGRESSION; CANCER RESISTANCE; CANCER STAGING; CANCER SUSCEPTIBILITY; CANCER THERAPY; CELL PROLIFERATION; GENE MUTATION; HUMAN; HUMAN GENOME; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOSURVEILLANCE; KAPOSI SARCOMA; METASTASIS INHIBITION; NONHUMAN; PATENT; PHASE 1 CLINICAL TRIAL (TOPIC); PRECANCER; REVIEW; RISK BENEFIT ANALYSIS; SOLID TUMOR; UNSPECIFIED SIDE EFFECT;

BACTERIA (MICROORGANISMS);

EID: 84858984935     PISSN: 14628732     EISSN: 1478565X     Source Type: Journal    
DOI: 10.5912/jcb.466     Document Type: Review

References (13)

1. Yamada, T. et al (2005) Internalization of bacterial redox protein azurin in mammalian cells: entry domain and specificity. Cellular Microbiology 7: 1418-1431. (Pubitemid 41335246)
2. Fialho, A.M. and Chakrabarty, A.M. (2010) Promiscuous anticancer drugs from pathogenic bacteria: rational versus intelligent drug design. In Emerging Cancer Therapy: Microbial Approaches and Biotechnological Tools. A.M. Fialho & A.M. Chakrabarty, Eds. P. 181-198. John Wiley & Sons, Hoboken, NJ.
3. Chaudhari, A. et al (2006) Azurin, Plasmodium falciparum malaria and HIV/AIDS: inhibition of parasitic and viral growth by azurin. Cell Cycle 5: 1642-1648. (Pubitemid 44285250)
4. Mehta, R.R. et al (2009) Compositions and methods to control angiogenesis with cupredoxins. US Patent 7,556,810 issued on July 07, 2009.
5. Yamada, T. et al. (2004) Apoptosis or growth arrest: modulation of tumor suppressor p53's specificity by bacterial redox protein azurin. Proceedings of the Naional Academy of Sciences of the United States of America. 101: 4770-4775. (Pubitemid 38469152)
6. Das Gupta, T.K and Chakrabarty, A.M. (2009) Compositions and methods to prevent cancer with cupredoxins. US Patent 7,618,939 issued on November 17, 2009.
7. Fialho, A.M. et al (2007) Beyond host-pathogen interactions: microbial defense strategy in the host environment. Current Opinion in Biotechnology 18: 279-286. (Pubitemid 46880281)
8. Mahfouz, M. et al. (2007) Bacterial proteins and CpG-rich extrachromosomal DNA in potential cancer therapy. Plasmid 57: 4-17. (Pubitemid 46054159)
9. Jia, L. et al (2010) Preclinical pharmacokinetics, metabolism, and toxicity of azurin-p28 (NSC745104) a peptide inhibitor of p53 ubiquitination. Cancer Chemotherapy & Pharmacology, in press.
10. Chaudhari, A. et al (2007) Cupredoxin-cancer interrelationship: azurin binding with EphB2, interference in EphB2 tyrosine phosphorylation and inhibition of cancer growth. Biochemistry 46: 1799-1810.
11. Fialho, A.M. and Chakrabarty, A.M., Editors. (2010) Emerging Cancer Therapy: Microbial Approaches and Biotechnological Tools. John Wiley & Sons, Hoboken, NJ.
12. Fialho, A.M. and Chakrabarty, A.M. (2010) The role and importance of intellectual property generation and protection in drug development. In Emerging Cancer Therapy: Microbial Approaches and Biotechnological Tools. A.M. Fialho & A.M. Chakrabarty, Eds. P. 405- 419. John Wiley & Sons, Hoboken, NJ
13. Fialho, A.M. and Chakrabarty, A.M. (2011) Law-medicine interfacing: patenting of human genes and mutations. Recent Patents on DNA & Gene Sequences 5: 81-85.